Plain language summary about GLP-1 treatments in people with metabolic dysfunction-associated steatotic liver disease

Plain Language SummaryWhat is metabolic dysfunction-associated steatotic liver disease?Metabolic dysfunction-associated steatotic liver disease, shortened to MASLD, is a medical condition caused by having too much fat in the cells of the liver, and is the most common cause of chronic liver disease worldwide. There are currently no medicines approved specifically to treat MASLD, and the condition is controlled by eating a healthy diet, being more physically active, and losing weight, which can reduce the build-up of fat in the liver.What is progression of MASLD and who is at risk?Researchers know that people with type 2 diabetes and/or obesity have a high risk of MASLD and around 20% to 30% of people with MASLD have inflammation inside the liver. When this inflammation happens, it’s called metabolic dysfunction-associated steatohepatitis or MASH for short. The risk of developing MASH is even higher in people who have both type 2 diabetes and are obese, have increased fat levels in the blood, are taking insulin, or are over 40 years of age. While we know leading a healthy lifestyle can help to reduce the risk or MASLD progressing to MASH, doctors really need medications to help people living with chronic liver disease.Could glucagon-like peptide 1 receptor agonists be used to treat MASLD?Glucagon-like peptide 1 receptor agonists, often referred to GLP-1 receptor agonists, are medications that help lower blood sugar levels by mimicking the GLP-1 hormone in the body. Activating the GLP-1 hormone triggers the body to produce more insulin, reduce the amount of sugar produced by the liver, slow down digestion, and reduce appetite. GLP-1 receptor agonists are currently approved as a treatment for people with type 2 diabetes and /or obesity, but researchers are looking into the potential use of GLP-1 receptor agonists for treating MASLD and MASH because of the link between these conditions, diabetes and obesity.This article summarizes what researchers know so far about MASLD, MASH and the use of GLP-1 receptor agonists to treat these chronic liver conditions.What were the main conclusions reported by the researchers?Doctors can identify and monitor MASLD and MASH to help patients to slow down the progression of liver damage by supporting them to make lifestyle changes. New treatments called GLP-1 receptor agonists and GLP-1 receptor agonist related therapies look promising in helping to treat people with MASLD and MASH by improving liver health, helping with weight loss, and reducing heart disease risks.This is an abstract of the Plain Language Summary of Publication article.View the full Plain Language Summary PDF of this article to read the full-text